Virtual Library
Start Your Search
Seung Joon Kim
Author of
-
+
P1.01 - Advanced NSCLC (ID 757)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.01-076 - Comparison of PANA Mutyper and PNA Clamping for Detecting KRAS Mutations in Tumor Tissue, Cell Block and Pleural Effusion from Cancer (ID 9920)
09:30 - 09:30 | Author(s): Seung Joon Kim
- Abstract
Background:
Recently, target therapy for cancer patients should be considered according to the individual mutational status. Therefore, detection of mutations is clinically important for patients’ outcome. Molecular testing of lung cancer is one of the most important standard of care and treatment. However, it is not always easy to get enough tumor tissue from patients. There is a promising novel mutation detection technology, which is PANA Mutyper. We compared effectiveness of both methods for the detection of KRAS mutation using tumor tissues, cell blocks and pleural effusions with patients with malignant pleural effusion.
Method:
: KRAS mutations were assessed by PANA Mutyper and PNA clamping using tumor tissues, cell blocks and pleural effusions. The diagnostic usefulness of two methods were analyzed.
Result:
A total of 104 patients with malignant pleural effusion were enrolled which includes 56 adenocarcinoma of lung, 11 squamous carcinoma of lung, 17 small cell lung cancer, 3 large cell lung cancer, 3 stomach cancer, 2 ovary cancer, etc. PANA Mutyper showed more superior detection rate than PNA clamping through tumor tissues, cell blocks and pleural effusions.
Conclusion:
PANA Mutyper had a diagnostic superiority for the detection of KRAS mutations in patients with malignant pleural effusion. This method can be used as more sensitive and accurate detection of KRAS mutations. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2014R1A2A1A11052422).
-
+
P2.02 - Biology/Pathology (ID 616)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.02-001 - Detection of Gene Fusions in NSCLC Using NGS Fusion Assay (ID 10033)
09:30 - 09:30 | Author(s): Seung Joon Kim
- Abstract
Background:
ALK/RET/ROS and MET exon 14 skipping detection are important to guide of treatment in non-small cell lung cancer (NSCLC) patients. Next generation sequencing (NGS) platform has been implemented in the daily practice for the diagnosis. However, the validation of the NGS-based panel is still complicated and difficult.
Method:
We developed NGS-based fusion assay panel to detect 183 total fusion variants including ALK/RET/ROS as well as MET exon 14 skipping. The fusion call agreement between OCP-50 NGS assay and Nanostring was performed. The result was compared with the FISH and IHC results. This study describes the validation of the assay to define assay parameters, performance characteristics and reproducibility across laboratories.
Result:
For the 55 samples analyzed, the results are as follows;ALK Fusion ROS1 Fusion RET Fusion METD14 NGS(+) NGS(-) Total NGS(+) NGS(-) Total NGS(+) NGS(-) Total NGS(+) NGS(-) Total NS (+) 20 0 20 6 0 6 5 0 5 0 0 0 NS (-) 1 33 34 1 47 48 0 49 49 2 52 54 Total 21 33 54 7 47 54 5 49 54 2 52 54
Conclusion:
The results of our study will be of help in learning the process of establishing, validating and applying the fusion gene detection method in NSCLCs. Furthermore, NGS based OCP-50 assay for fusion detection is more accurate and reliable method for the diagnosis.
-
+
P3.01 - Advanced NSCLC (ID 621)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.01-057 - Comparison of EGFR Mutations in Matched Tumor Tissues, Cell Blocks, Pleural Effusions and Bloods with NSCLC, by PANA Mutyper and PNA Clamping (ID 9829)
09:30 - 09:30 | Presenting Author(s): Seung Joon Kim
- Abstract
Background:
There has been a marvelous paradigm shift in the diagnosis and management of lung cancer, with the discovery of driver mutations that can be targeted by specific inhibitors. Personalized therapy is driving the demand for mutation testing in cancer. Especially, molecular testing of lung adenocarcinoma for the epidermal growth factor receptor (EGFR) is now considered one of the most important standard of care with other driver mutations. However, sampling tumor tissue other than surgical resection has inevitable limitations. It may be difficult to obtain enough DNA for EGFR mutation test if biopsy tissue was inadequate. There is a promising ctDNA detection technology, that is PANA Mutyper technology, which is a novel technology that integrates PNA clamp and PANA S-melting. We investigated effectiveness of both methods for the detection of EGFR mutation.
Method:
Ninety patients with malignant pleural effusion of lung cancer were enrolled. EGFR mutations were assessed by PANA Mutyper and PNA clamping using tumor tissues, cell blocks, pleural effusions, and bloods separated by serum and plasma. The diagnostic performance of both methods was investigated.
Result:
Among the 90 patients with malignant pleural effusion of lung cancer, 56 patients were adenocarcinoma of lung, 11 were squamous carcinoma of lung, and 17 were small cell lung cancer. PANA Mutyper using bloods showed that 70% sensitivity, 100% specificity, 100% positive predictive value and 83% negative predictive value comparing to the combination of PANA Mutyper and PNA clamping through tumor tissues, cell blocks and pleural effusions (p=0.014).
Conclusion:
PANA Mutyper using bloods had a diagnostic performance for the detection of EGFR mutations in NSCLC that was comparable to that of tumor tissues, cell blocks and pleural effusions. The diagnostic performance of PANA Mutyper was better than that of PNA clamping. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2014R1A2A1A11052422).
